|
|
Post by goyocafe on Aug 29, 2018 16:41:35 GMT -5
Other than the Mannkind website, has anyone seen any publications in August? I don’t recall seeing anything.
|
|
|
|
Post by mnholdem on Aug 29, 2018 16:57:12 GMT -5
|
|
|
|
Post by goyocafe on Aug 29, 2018 17:17:38 GMT -5
Thanks for the links. I guess I didn’t realize these met the criteria, but glad to learn something. |
|
|
|
Post by mnholdem on Aug 29, 2018 19:46:19 GMT -5
Certainly the John E. Anderson publication in The Journal of Family Practice qualifies since it presents Afrezza and recent data supporting inhaled prandial insulin. I get the gist of your post, though, in light of Dr. Kendall's recent comments that several publications will be released in the coming months. In September, two active clinical studies are scheduled to complete their primary outcomes: the Baltimore study on introducing Afrezza in early diabetes and the Afrezza-OneDrop study. Both have primary outcomes which measure reduction of A1c levels. It's an antiquated measurement, but one that's still accepted by the medical community. Publication dates for these two studies should be in the October/November timeframe, IMO. Finally, there is Dr Kendall's presentation at the EASD 2018 annual meetings. Publication of Kendall's findings likely cannot be published before the Oct 2-5 meetings in Germany and, I believe, will involve CT SCAN stats mined from data of past clinical studies. I think these findings will be significant and may even impact the FDA-mandated post-market lung safety study. Kendall's October presentation will be the 2nd publication mined from past studies, what MannKind's CMO labeled as 'veins of gold'.  |
|
|
|
Post by brotherm1 on Aug 29, 2018 20:14:04 GMT -5
Much appreciated mnholdem. With so much negative minutia posted by some, it’s sometimes hard to keep track of and remember the important facts.
|
|
|
|
Post by agedhippie on Aug 30, 2018 7:19:47 GMT -5
|
|
|
|
Post by mnholdem on Aug 30, 2018 7:57:22 GMT -5
It appears that MannKind’s new CMO is earning his pay.
|
|
|
|
Post by xanet on Aug 30, 2018 9:52:26 GMT -5
|
|
|
|
Post by mike0475 on Aug 30, 2018 10:00:32 GMT -5
behind paywall - does MNKD get any cash from this set up?
|
|
|
|
Post by xanet on Aug 30, 2018 10:02:12 GMT -5
behind paywall - does MNKD get any cash from this set up? No, this paper wasn't written by MNKD. A paywall is how journals like this stay in business. Unless you were joking, then that was pretty funny! |
|
|
|
Post by bundy on Aug 30, 2018 13:13:09 GMT -5
Amazing mh doesn’t even mention afrezza once. So tough if even an afrezza user doesn’t mention it at all in his article.
|
|
Found another poster session as well! : 